NCT05767905View on ClinicalTrials.gov

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Healthy
Interventions
DRUG

PF-06821497 Treatment A

A single dose of PF-06821497 administered under fasting conditions.

DRUG

PF-06821497 Treatment B

A single dose of PF-06821497 administered under fasting conditions.

DRUG

PF-06821497 Treatment C

A single dose of PF-06821497 administered under fasting conditions.

DRUG

PF-06821497 Treatment D

A single dose of PF-06821497 administered under fasting conditions.

DRUG

PF-06821497 Treatment E

A single dose of PF-06821497 administered after low fat meal

DRUG

PF-06821497 Treatment F

A single dose of PF-06821497 administered after high fat meal.

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05767905 - A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants. | Biotech Hunter | Biotech Hunter